Literature DB >> 23749996

99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization.

Maurits Wondergem1, Maarten L J Smits, Mattijs Elschot, Hugo W A M de Jong, Helena M Verkooijen, Maurice A A J van den Bosch, Johannes F W Nijsen, Marnix G E H Lam.   

Abstract

UNLABELLED: In hepatic (90)Y radioembolization, pretreatment (99m)Tc-macroaggregated albumin ((99m)Tc-MAA) nuclear imaging is used for lung shunt analysis, evaluation of extrahepatic deposition, and sometimes for treatment planning, using a partition model. A high level of agreement between pretreatment (99m)Tc-MAA distribution and final (90)Y-microsphere distribution is assumed. The aim of this study was to investigate the value of pretreatment (99m)Tc-MAA SPECT to predict intrahepatic posttreatment (90)Y-microsphere distribution.
METHODS: Volumes of interest (VOIs) were delineated on pretreatment contrast-enhanced CT or MR images according to Couinaud liver segmentation. All VOIs were registered to the (99m)Tc-MAA SPECT and (90)Y SPECT images. The (99m)Tc-MAA SPECT and (90)Y SPECT activity counts were normalized to the total administered activity of (90)Y. For each VOI, this practice resulted in a predictive amount of (90)Y (MBq/cm(3)) based on (99m)Tc-MAA SPECT in comparison with an actual amount of (90)Y based on (90)Y SPECT. Bland-Altman analysis was used to investigate the agreement of the activity distribution between (99m)Tc-MAA SPECT and (90)Y SPECT.
RESULTS: A total of 39 procedures (225 VOIs) in 31 patients were included for analysis. The overall mean difference between pretreatment and posttreatment distribution of activity concentration for all segments was -0.022 MBq/cm(3) with 95% limits of agreement of -0.581 to 0.537 MBq/cm(3) (-28.9 to 26.7 Gy absorbed dose). A difference of >10%, >20%, and >30% of the mean activity per milliliter was found in, respectively, 153 (68%), 97 (43%), and 72 (32%) of the 225 segments. In every (99m)Tc-MAA procedure, at least 1 segment showed an under- or overestimation of >10%. The position of the catheter tip during administrations, as well as the tumor load of the liver segments, significantly influenced the disagreement.
CONCLUSION: In current clinical practice, (99m)Tc-MAA distribution does not accurately predict final (90)Y activity distribution. Awareness of the importance of catheter positioning and adherence to specific recommendations may lead to optimization of individualized treatment planning based on pretreatment imaging.

Entities:  

Keywords:  90Y microspheres; 99mTc-MAA; dosimetry; liver; radioembolization

Mesh:

Substances:

Year:  2013        PMID: 23749996     DOI: 10.2967/jnumed.112.117614

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  60 in total

Review 1.  Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know.

Authors:  Alexander Villalobos; Mohamed M Soliman; Bill S Majdalany; David M Schuster; James Galt; Zachary L Bercu; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

Review 2.  Update on novel trends in PET/CT technology and its clinical applications.

Authors:  Stephan Walrand; Michel Hesse; François Jamar
Journal:  Br J Radiol       Date:  2016-11-25       Impact factor: 3.039

3.  Personalized Dosimetry for Liver Cancer Y-90 Radioembolization Using Computational Fluid Dynamics and Monte Carlo Simulation.

Authors:  Emilie Roncali; Amirtahà Taebi; Cameron Foster; Catherine Tram Vu
Journal:  Ann Biomed Eng       Date:  2020-01-31       Impact factor: 3.934

4.  Practical reconstruction protocol for quantitative (90)Y bremsstrahlung SPECT/CT.

Authors:  W Siman; J K Mikell; S C Kappadath
Journal:  Med Phys       Date:  2016-09       Impact factor: 4.071

Review 5.  The role of SPECT/CT in radioembolization of liver tumours.

Authors:  Hojjat Ahmadzadehfar; Heying Duan; Alexander R Haug; Stephan Walrand; Martha Hoffmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-18       Impact factor: 9.236

6.  Assessing Spatial Concordance Between Theranostic Pairs Using Phantom and Patient-Specific Acceptance Criteria: Application to 99mTc-MAA SPECT/90Y-Microsphere PET.

Authors:  Justin K Mikell; Bill S Majdalany; Dawn Owen; Kelly C Paradis; Yuni K Dewaraja
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-04-22       Impact factor: 7.038

7.  166Ho microsphere scout dose for more accurate radioembolization treatment planning.

Authors:  C Chiesa; M Maccauro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04       Impact factor: 9.236

8.  Feasibility of imaging 90 Y microspheres at diagnostic activity levels for hepatic radioembolization treatment planning.

Authors:  Britt Kunnen; Martijn M A Dietze; Arthur J A T Braat; Marnix G E H Lam; Max A Viergever; Hugo W A M de Jong
Journal:  Med Phys       Date:  2020-01-20       Impact factor: 4.071

9.  Selective Internal Radiation Therapy With Yttrium-90 Glass Microspheres: Biases and Uncertainties in Absorbed Dose Calculations Between Clinical Dosimetry Models.

Authors:  Justin K Mikell; Armeen Mahvash; Wendy Siman; Veera Baladandayuthapani; Firas Mourtada; S Cheenu Kappadath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-07-27       Impact factor: 7.038

10.  A review of 3D image-based dosimetry, technical considerations and emerging perspectives in 90Y microsphere therapy.

Authors:  Jim O' Doherty
Journal:  J Diagn Imaging Ther       Date:  2015-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.